Documente Academic
Documente Profesional
Documente Cultură
Anil K. Shukla1,*, Ashutosh Katole2, Nilesh Jain1, C. Karthikeyan1, Farhad Mehta1 and Piyush Trivedi1
1
School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India 2 Ranbaxy Laboratories Limited, Industrial Area 3, Dewas, Madhya Pradesh, India
Abstract
In the pharmaceutical industry qualication of HVAC systems is done by using a risk based approach. Failure mode effect analysis (FMEA) concepts were used for risk assessment of a HVAC system to determine the scope and extent of qualication and validation in this present work. The HVAC is the direct impact system in the aseptic practice which directly affects the product quality and regulatory compliance. The level of risk associated with the HVAC system was assessed based on the impact and severity of the probable risk in aseptic practice in sterile manufacturing. On completion of the risk assessment, control and measures developed and recommended actions for unacceptable risk were identied for improved cGMP compliance and qualication of the system upgrades. After completion of the risk assessment the recommended actions were extended and veried against the qualication stages of the HVAC system. Finally, the HVAC system was subjected to a performance qualication (PQ) study. All of the tests were performed and a report was generated. On evaluation of the data collected during PQ, it was found that the HVAC system met all the specied design criteria and complied with the entire cGMP requirement. Hence the system stands validated for PQ. Copyright 2011 John Wiley & Sons, Ltd.
Key Words: HVAC; UAF; PQ; ICH; FMEA
Introduction
Quality risk management is an important part of science based decision making which is essential
*Correspondence to: Anil Shukla, School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India. E-mail: aksqargpv@gmail.com
for quality management of pharmaceutical manufacturing. The ICH Q9 guideline, quality risk management and other literature provide guidance on the principal of quality risk management. The FMEA model can be used to facilitate risk assessment for any system in the aseptic processing area of sterile products. It
Qualication of HVAC System in Aseptic Processing Area Table 1. Risk ranking system
Qualitative ranking High Medium Low Risk factor Severity Impact of unwanted event is severe Impact of unwanted event is moderate Impact of unwanted event is low Occurrence Occurrence is often Occurrence is periodic Occurrence is seldom Detection The process failure will almost certainly escape detection Control may detect the existence of a process failure The process failure is obvious and readily detected
41
provides a tool to assess and evaluate different activities and conditions. Risk ranking system in FMEA model is given in Table 1. Risk in sterile product manufacturing and aseptic processing is relatively high when compared to other pharmaceutical process, making risk assessment particularly important [110]. The European Union GMP requirements place specic obligations on manufacturers of medicinal products to implement risk based qualication, validation and change control programs. In pharmaceutical manufacturing, validation is an important part of QA and is a requirement of cGMP and other guidelines [11,1416]. In the air handling system, special attention must be made to keep the environment clean and prevent product contamination. From a technical perspective, the role of the HVAC system is paramount in achieving and maintaining an acceptable manufacturing environment.
represented the risk priority ranking system as per the FMEA model. After completion of the risk assessment, the recommended action of unacceptable risk extended to qualication stages of HVAC system to have a high level of assurance and if the test result are not acceptable, carry out corrective action that may include modication in the existing controls and the system.
Performance Qualication for HVAC and Unidirectional Air Flow (UAF) System Air Velocity and Air Changes
Velocity at the inlet air grills was measured at 5 points in a plane parallel to lter face plane and at a distance of about 6 inches (~ 150mm) from the lter/opening face. The velocity was measured for at least 10 seconds from each point. It is performed by thermal anemometer and vane type anemometer and calculated by formula where, D is no. of air changes, B is air supply volume (CFM), R is volume of the room (ft3), 60 is factor (for air change per hour) [1820]. P D B 60 R
42
A. K. Shukla et al.
Medium
This could occur and it could be detected. Depending on our confidence in the detection, its risk would be Medium or High Risk. The cause is not likely to occur and if it did, it may be detected. Depending on the frequency of occurrence and the confidence in detection method, it would be a Low or Medium Risk.
This may occur and it will not be detected The Risk is High.
Low
The cause is not likely to occur but if it did occur, it probably would not be detected. The Risk is Medium.
concentration of 20-100mg/m (20100 mg/lit.) of air by opening appropriate number of nozzles. Measure upstream concentration of aerosol by using upstream port. Adjust the photometers gain / span control for a full-scale deection on 100% range. Scan the downstream side of the HEPA lter. The photometer probe should be about 1 inch from the surface and at a transverse rate not more than 10ft/minute with a sample ow rate of 1cft/min 10% [1820,32,34].
NL A Volume of sample (for grade A at rest and operation,gradeBatrest)-1m3 equivalentto35.3ft3 Volume of sample (for grade B at operation and other grades at both conditions) -1 ft3 [1720,27,28].
Qualication of HVAC System in Aseptic Processing Area Table 3. Risk assessment for HVAC system
Description of identied risk (unwanted events) New equipment facility or system or any major change in the existing equipment may affect the product requirement safety feature and environment. Air/energy losses may occur during air distribution through ducts. Contamination due to air leakage when AHU is shutdown. (negative pressure may lead to contamination) 3 Installation of component at inappropriate places leading to inadequate performance of AHU. Inappropriate operation of AHU may lead to noncompliance with respect to performance requirement and frequent maintenance. Blocking of the filter affected the differential pressure level and may lead to contamination High Likelihood of occurrence (probability and frequency) Low URS and vendor DQ are in place. Risk related to Probability of detection High If any mismatch observed between user and supplier specication. Risk priority rank High Risk accepted? (yes/no) No
43
Risk no. 1
Recommended action User and supplier specifications and drawings are evaluated for their compliance to the intended use and cGMP during DQ.
Medium
Low Sheets are lock forming quality. lock. Insulation thermocole. Claddingaluminum.
Medium
No
Duct leakage should be checked through smoke test and reports addressed in the IQ.
High
No
High
High If the operating and maintenance person are not trained with respect to the related SOP.
High
No
High
Low Differential pressure monitoring switches are placed across the lter.
High
No
DP switches are provided across HEPA filter for monitoring the blocking of the filter and feedback given
44
A. K. Shukla et al.
Table 3. Continued
Description of identied risk (unwanted events) in area at higher cleanliness class. 6 Uncalibrated instrument affected the monitoring and controlling the desired product environment condition. Failure of Audio/ visual indication of alarms may not alert the personnel and will continue to operate in noncomplying conditions. High Likelihood of occurrence (probability and frequency) Pre lters are in place. Risk related to Probability of detection Risk priority rank Risk accepted? (yes/no)
Risk no.
Impact (severity)
Medium Instrument/ component are identied for calibration with tag no.
High
No
Instrument/ component should be calibrated (temp., RH, DP) and report addressed in the OQ.
High
Medium List of all alarms are veried and classied in critical/ non critical on the basis of impact on product quality/purity.
High If the alarms are not generated during the excursion in temperature/ RH/DP beyond the set limit.
High
No
All alarms should be checked, verified and set the parameters related to safety of product/ person/ environment during OQ.
Air velocity and air changes may affect the cleanliness class, heat load and recovery from contamination.
High
Medium Supply and return air volume (CFM) of AHU are as per requirement of area and occupancy.
High If there is no check done to verify the air velocity air changes per hour (ACPH).
High
No
The air velocity and ACPH should be checked by anemometer to ensure that adequate amount of air is supplied in the room and report addressed in the PQ. DP should be checked through magnehelic gauge to verify the capability of complete installation to maintain the specified pressure difference and report addressed in PQ. The integrity should be checked through DOP test and report addressed
Differential pressure is critical for maintaining cleanliness class and cross contamination.
High
Low DP gauge continuous monitor the pressure difference between different class room (one for each room separately).
High If differential pressure value less than alarm limit and greater than specied time between similar and non similar classes.
High
No
10
The validation status with respect to the filter integrity may be affected.
High
High
No
45
Risk no.
Impact (severity)
Non unidirectional air flow should be checked through WFI fogger and report addressed in the PQ.
High
No
Unidirectional air flow should be checked through WFI fogger; the air flow should have a sweeping action over and away from the product under dynamic condition and report addressed in the PQ. Airborne particle count should be checked through particle counter to Determine the cleanliness level as per ISO standards.
13
Air cleanliness in clean rooms may affect the contamination sensitive activities.
High
Low Final ltration of supply air in the room through terminal mounted HEPA lter (H-13) efciency 99.97% down to 0.3 micron particles.
High
No
14
Airborne particle concentration may affect the specification of air cleanliness in clean rooms.
High
Medium Environmental monitoring devices are in place (FMS). Final ltration of supply air in the room
High If there is no check done to verify the integrity of lters and air velocity.
High
No
Recovery/ decontamination rate test should be checked through DOP test in classified area and recovery report addressed in the PQ.
46
A. K. Shukla et al.
Table 3. Continued
Description of identied risk (unwanted events) Likelihood of occurrence (probability and frequency) through terminal mounted HEPA lter. 15 Temperature may lead to product instability, personnel discomfort and microbial growth. Relative humidity may affect the moisture sensitive activity. High Low Temperature sensors are located in each room and common return air duct. High Low RH sensors are provided for common return air duct. Dehumidier is in place. High Medium Alert and action limits are determined by trends analysis. High Excursion of temperature beyond the set limit due to different operation. High Excursion of RH beyond the set limit due to CIP/SIP operation. High No High No Temperature should be checked through calibrated instrument and report addressed in the PQ. Risk related to Probability of detection Risk priority rank Risk accepted? (yes/no)
Risk no.
Impact (severity)
Recommended action
16
RH should be checked through calibrated hygrometer and report addressed in the PQ.
17
High
No
Viable count should be monitored through settle plate, air sampling, swab sampling and report addressed in the PQ.
7 8 9 10
condition at rest condition at operational condition Recovery/decontamination rate test Environmental conditions -Temperature Environmental conditions - Relative humidity Viable count monitoring Sampling active air sampling settle plate method
Class area With in class B With in class B Within 10 min 22 3 C NMT 20% Class area With in class B With in class B
Qualication of HVAC System in Aseptic Processing Area Table 5. Performance Qualication of UAF System
S. No 1 2 3 4 Air velocity Differential pressure test HEPA filter integrity test Air flow visualization (unidirectional flow) Test performed Acceptance criteria 9020 FPM at 6 inch. From filter face NLT 10mm of WC Less than 0.01% of upstream conc. Flow should be unidirectional Results Complies
47
condition at rest condition at operational condition Sampling active air sampling swab sampling method
Class area With in class A With in class A Class area With in class A With in class A
14 to 16mm of WC Max. 0.002 % Meeting the acceptance criteria under dynamic condition 0.5 mm 5 mm 0 0 247 0 TBC <1 <1 TFC <1 <1
Results
Performance qualication of HVAC system was done using risk assessment approach. Table 3 shows the risk assessment of HVAC system. Tables 4 and 5 represented the performance qualication parameters of HVAC and UAF system, specications and results observed.
Conclusion
Qualication and validation is appearing to be the beginning of a continuous development process in pharmaceutical QA. Risk assessment is an essential tool for qualication of HVAC system in aseptic processes. It is not just a tool for cGMP compliance, its offers real benets to the validation process by identifying risks and ensuring that critical risks are controlled. By focusing on managing risks to the patient, pharmaceutical manufacturers can ensure that the right resources are applied at the right place and at the right time improving patient safety while eliminating unnecessary qualication and validation efforts.
References
1. WHO. Annex 4, Supplementary Guidelines on
48
A. K. Shukla et al.
Health Organization. Technical Report Series, No. 937, 2006, 116121. 2. Sugarman Samuel C. HVAC Fundamentals. The Fairmont press, Inc; 2005, 13. 3. FDA. Guidance for Industry. Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice, Food and Drug Administration. Rockville, MD, 2004, 46. 4. Nash Robert A, Wachter Alfred H. Qualication of water and air handling systems. Pharmaceutical Process Validation, 3rd ed. vol. 129. Marcel Dekker, 2224. 5. WHO. Supplementary Training Modules on Good Manufacturing Practice, Heating Ventilation and Air Conditioning (HVAC) Part 1 (a). Introduction and Overview Technical Report Series, no. 937, 2006, 126. 6. Swarbrick J. Encyclopedia of Pharmaceutical Technology, 3rd ed. vol. 1. USA: Informa health care, 127128. 7. Annex 1. EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use. Manufacture of Sterile Medicinal Products, vol. 4. March 2009, 29. 8. Agalloco JP, Carleton FJ. Validation of Aseptic Pharmaceutical Process. 2nd ed. New York: Marcel Dekker, Inc., 23. 9. WHO. Supplementary Guidelines on Good Manufacturing Practices (GMP): Validation, June 2004, 715. 10. ICH Q9. Quality Risk Management. Current Step 4 Version, November 2005. 11. Annex 20. EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use. Quality Risk Management, vol. 4, March 2008. 12. PDA. Technical Report No. 44: Quality Risk Management for Aseptic Processes. Supplement to the PDA Journal of Pharmaceutical Science and Technology, vol. 62, 2008, 614. 13. McDermott RE, Mikulak RJ, Beauregard MR. The Basics of FMEA. Portland: Productivity, Inc; 1995, 344. 14. Annex 15. EU Guide to Good Manufacturing Practice. Qualication and validation, 2001, 37. 15. ISPE Baseline Guide. Commissioning and Qualication, vol. 5, 2001. 16. Potdar AM. Pharmaceutical Quality Assurance, 2nd ed. Pune: Nirali Prakashan, 2007, 8.6
17. ISO 146441. Cleanrooms and Associated Controlled Environments, Part-1: Classication of Air Cleanliness, 1999(E), 14. 18. ISO 146442. Cleanrooms and Associated Controlled Environments, Part-2: Specications for Testing and Monitoring to Prove Continued Compliance with ISO 146441, 2000(E), 14. 19. ISO 146443. Cleanrooms and Associated Controlled Environments, Part 3: Metrology & Test Methods, 2005(E), 13. 20. A working group of the Scottish Quality Assurance Specialist Interest Group. Guideline On Test Methods For Environmental Monitoring For Aseptic Dispensing Facilities, 2nd ed. February 2004, 36. 21. Health Canada, Process Validation. Aseptic Processes for Pharmaceuticals, Health Products and Food Branch Inspectorate, Guide, June 2003, 1012. 22. ICH Q10. Pharmaceutical Quality System, Current Step 4 Version, June 2008. 23. Garvey W. Essentials of validation project management part-I. Pharm Technol 2005: 16. 24. Akers JE, Agalloco JP. The simplied AkersAgalloco method for aseptic processing risk analysis. Pharm Technol 2006: 18. 25. Lander V. 21 CFR part 11 and risk assessment: adapting fundamental methodologies to a current rule. Pharm Technol Eur 2004: 13. 26. Drakulich A. Risk management: practical applications and value. EPT--The Electronic Newsletter of Pharmaceutical Technology 2007, 12. 27. Del Valle MA. Keeping clean rooms compliant. Pharm Technol Eur 2006;18(11):14. 28. Straker M. Clean rooms and air handling systems: design for compliance. Pharm Technol Eur 2005:13. 29. Tidswell EC, McGarvey B. Quantitative risk modeling in aseptic manufacture. PDA J Pharm Sci Technol September 2006;60:267269. 30. Li J, Poulton G. Dynamic zone modeling for HVAC system control. Int J Model Ident Control April 2010;9:514. 31. PIC document PE 0091. Guide to Good Manufacturing Practice for Medicinal Products, September 2003, 27. 32. Dixon AM. Environmental Monitoring for Clean Rooms and Controlled Environments, Drugs and the Pharmaceutical Sciences, vol. 164. USA: Informa Health Care; 206210. Qual Assur J 2011; 14, 4049 DOI: 10.1002/qaj
49
33. McDowall R. Fundamentals of HVAC Systems, inch edition. USA: American society of heating, refrigerating and air-conditioning Engineers Inc.; 2006, 26. 34. ISO 146444. Cleanrooms and Associated Controlled Environments-Part 4: Design, Construction and Startup, 24. 35. WHO. Guide To Good Manufacturing Practice (GMP) Requirements, Part 2: Validation. Geneva: World Health Organization; 1997, 2432. 36. PIC/S. Guide to Good Manufacturing Practice for Medicinal Products. Pharmaceutical Inspection
Convention, Pharmaceutical Inspection Co-Operation Scheme, PE 0095, August 2006, 612. 37. WHO. Annex 6, Good Manufacturing Practices for Sterile Pharmaceutical Products, World Health Organization. Technical Report Series, No. 902, 2002. 38. FDA. Pharmaceutical cGMP for The Twenty First Century: A Risk Based Approach. Food and Drug Administration, Rockville, MD, September 2004. 39. Akers J, Agalloco JP. Risk analysis for aseptic processing: the Akers- Agalloco method. Pharmaceutical Technology 2005, 35.